Divi's Laboratories Limited (IN:DIVISLAB)
:DIVISLAB
Want to see IN:DIVISLAB full AI Analyst Report?
DIVISLAB Stock Chart & Stats
₹6603.05
-₹20.75(-0.35%)
At close: 4:00 PM EST
₹6603.05
-₹20.75(-0.35%)
Day’s Range― - ―
52-Week Range₹5,637.50 - ₹7,077.70
Previous CloseN/A
Volume63.15K
Average Volume (3M)6.36K
Market Cap
₹1.69T
Enterprise Value₹1.69T
Total Cash (Recent Filing)₹32.61B
Total Debt (Recent Filing)₹900.00M
Price to Earnings (P/E)72.7
Beta0.81
Next Earnings
May 25, 2026EPS Estimate
26.43Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)21.98
Shares Outstanding265,468,570
10 Day Avg. Volume6,055
30 Day Avg. Volume6,356
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)9.84
Price to Sales (P/S)15.80
P/FCF Ratio290.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)117.73
Revenue Forecast (FY)₹123.34B
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage and a high equity ratio provide durable financial flexibility for Divi's. Strong ROE (14.6%) indicates effective capital deployment, enabling sustained reinvestment in capacity, process improvements or selective M&A without stressing solvency over the next several quarters.
Solid Operating Cash GenerationConsistent positive operating cash flow with coverage >1 shows the core API/CRAMS business converts earnings into cash, supporting capex and working capital needs. This cash-generation ability underpins long-term investment in manufacturing scale and continuity of supply to global customers.
Diversified API And CDMO Revenue MixA dual business model—volume generic API supply plus custom synthesis/contract manufacturing—provides structural diversification. Long-term CRAMS contracts and process chemistry capabilities give multi-year revenue visibility and higher-value project opportunities that reduce dependence on commoditized pricing.
Bears Say
Volatile Free Cash FlowExtreme FCF volatility, flagged as an 'Infinity' increase, suggests inconsistent cash conversion from earnings or timing anomalies. This undermines predictability for capex, dividends or buybacks and raises execution risk when scaling plants or funding long CRAMS projects over the coming quarters.
Significant Gross Margin DeclineA structural fall in gross margin of this magnitude points to mix shifts, pricing pressure, or rising input costs. Sustained lower gross margins would compress operating leverage, reduce cash generation potential and limit reinvestment capacity, challenging long-term margin sustainability.
Slowing Recent Revenue GrowthRecent top-line growth has slowed to ~3.1% in the latest period versus stronger historical trends. Slower revenue expansion limits margin expansion opportunities and reduces visibility on capacity utilization and CRAMS ramp timing, making multi-quarter planning and returns on new investments less certain.
Divi's Laboratories Limited News
DIVISLAB FAQ
What was Divi's Laboratories Limited’s price range in the past 12 months?
Divi's Laboratories Limited lowest stock price was ₹5637.50 and its highest was ₹7077.70 in the past 12 months.
What is Divi's Laboratories Limited’s market cap?
Divi's Laboratories Limited’s market cap is ₹1.69T.
When is Divi's Laboratories Limited’s upcoming earnings report date?
Divi's Laboratories Limited’s upcoming earnings report date is May 25, 2026 which is in 27 days.
How were Divi's Laboratories Limited’s earnings last quarter?
Divi's Laboratories Limited released its earnings results on Feb 11, 2026. The company reported ₹21.98 earnings per share for the quarter, missing the consensus estimate of ₹23.173 by -₹1.193.
Is Divi's Laboratories Limited overvalued?
According to Wall Street analysts Divi's Laboratories Limited’s price is currently Overvalued.
Does Divi's Laboratories Limited pay dividends?
Divi's Laboratories Limited pays a Annually dividend of ₹30 which represents an annual dividend yield of 0.46%. See more information on Divi's Laboratories Limited dividends here
What is Divi's Laboratories Limited’s EPS estimate?
Divi's Laboratories Limited’s EPS estimate is 26.43.
How many shares outstanding does Divi's Laboratories Limited have?
Divi's Laboratories Limited has 265,468,570 shares outstanding.
What happened to Divi's Laboratories Limited’s price movement after its last earnings report?
Divi's Laboratories Limited reported an EPS of ₹21.98 in its last earnings report, missing expectations of ₹23.173. Following the earnings report the stock price went up 4.889%.
Which hedge fund is a major shareholder of Divi's Laboratories Limited?
Currently, no hedge funds are holding shares in IN:DIVISLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Divi's Laboratories Limited
Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and supplies a range of carotenoids, as well as markets vitamins to nutritional, pharma, food/beverage, and feed industries. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.
Technical Analysis
Dr. Reddy's Laboratories Ltd.
―
Laurus Labs Ltd.
―
Lupin Limited
―
Suven Life Sciences Limited
―
Torrent Pharmaceuticals Ltd
―